Quick answers
- What is Doxepin hydrochloride used for?
- The FDA-approved label (Zonalon, Mylan Pharmaceuticals Inc., June 14, 2017) says: “Zonalon ® Cream is indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus. (See DOSAGE AND ADMINISTRATION.)” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Doxepin hydrochloride have a boxed warning?
- The label we quote has no boxed warning, but 74 of 99 FDA labels for this medicine do. Check the label of your own product.
- Is there a shortage of Doxepin hydrochloride?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Doxepin hydrochloride been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started July 25, 2025 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Doxepin hydrochloride?
- 50 companies list prescription products of Doxepin hydrochloride in the FDA NDC Directory, including Bryant Ranch Prepack, Remedyrepack Inc. and Mylan Pharmaceuticals Inc..
What Doxepin hydrochloride is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Zonalon ® Cream is indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus. (See DOSAGE AND ADMINISTRATION.)
— FDA label: Zonalon, Mylan Pharmaceuticals Inc., effective June 14, 2017. Read the full label on DailyMed →
The FDA has 99 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
74 of 99 FDA labels for this medicine have a boxed warning.
Forms and how it is given
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| doxepin hydrochloride 10 mg capsule | Generic | $0.0796 per capsule |
| doxepin hydrochloride 10 mg/mL solution | Generic | $0.8878 per mL |
| doxepin hydrochloride 100 mg capsule | Generic | $0.3017 per capsule |
| doxepin hydrochloride 25 mg capsule | Generic | $0.1476 per capsule |
| doxepin hydrochloride 3 mg tablet | Generic | $1.37 per tablet |
| doxepin hydrochloride 3 mg tablet, film coated | Generic | $1.37 per tablet |
| doxepin hydrochloride 5% cream | Generic | $7.85 per gram |
| doxepin hydrochloride 50 mg capsule | Generic | $0.1641 per capsule |
| doxepin hydrochloride 6 mg tablet | Generic | $1.41 per tablet |
| doxepin hydrochloride 6 mg tablet, film coated | Generic | $1.41 per tablet |
| doxepin hydrochloride 75 mg capsule | Generic | $0.2237 per capsule |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack19 products
- Remedyrepack Inc.11 products
- Mylan Pharmaceuticals Inc.8 products
- Novadoz Pharmaceuticals LLC7 products
- Aurobindo Pharma Limited7 products
- Ajanta Pharma USA Inc.7 products
- Leading Pharma, LLC6 products
- Direct_Rx6 products
- PD-Rx Pharmaceuticals, Inc.5 products
- Puracap Laboratories LLC dba Blu Pharmaceuticals5 products
- Alembic Pharmaceuticals Limited5 products
- Rising Pharma Holdings, Inc.5 products
- Florida Pharmaceutical Products, LLC5 products
- First Nation Group, LLC5 products
- Contract Pharmacal Corp.5 products
- Appco Pharma LLC5 products
- Amneal Pharmaceuticals LLC5 products
- Proficient Rx LP5 products
- NorthStar RxLLC5 products
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.5 products
- Epic Pharma, LLC5 products
- Chartwell RX, LLC5 products
- Lifestar Pharma LLC5 products
- Alembic Pharmaceuticals Inc.5 products
- Major Pharmaceuticals4 products
- Mylan Institutional Inc.4 products
- Golden State Medical Supply, Inc.4 products
- Safecor Health LLC4 products
- A-S Medication Solutions4 products
- Sun Pharmaceutical Industries, Inc.3 products
- NorthStar Rx LLC2 products
- Actavis Pharma, Inc.2 products
- Viona Pharmaceuticals Inc2 products
- Archis Pharma LLC2 products
- Marlex Pharmaceuticals, Inc.2 products
- Boswell Pharmacy Services LLC d/b/a BPS Wholesale2 products
- Strides Pharma Science Limited2 products
- Aphena Pharma Solutions - Tennessee, LLC2 products
- Currax Pharmaceuticals LLC2 products
- Coupler LLC2 products
- Zydus Lifesciences Limited2 products
- North Star Rx LLC2 products
- Currax Pharmaceuticals LLC dba Cypress, Hawthorn, Macoven2 products
- NuCare Pharmaceuticals, Inc.1 product
- Teva Pharmaceuticals USA, Inc.1 product
- Advanced Rx Pharmacy of Tennessee, LLC1 product
- Advanced Rx of Tennessee, LLC1 product
- Redpharm Drug1 product
- Amneal Pharmaceuticals NY LLC1 product
- Lannett Company, LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA020126 ZONALON | Mylan | April 1, 1994 | 5, latest December 20, 2002 2002: Labeling · 1996: Manufacturing (CMC) · 1995: Manufacturing (CMC) |
| NDA022036 SILENOR | Currax | March 17, 2010 | 4, latest October 29, 2020 2020: Labeling · 2016: Manufacturing (CMC) · 2014: Manufacturing (CMC) |
Generic approvals (27)
- ANDA070791Mylan Pharms Inc · May 13, 1986
- ANDA074721Lannett Co Inc · December 29, 1998
- ANDA201951Actavis Elizabeth · July 26, 2013
- ANDA202337Rk Pharma · January 20, 2016
- ANDA207482Amneal Pharms Co · June 28, 2017
- ANDA211603Aurobindo Pharma Ltd · March 27, 2019
- ANDA212624Ajanta Pharma Ltd · September 13, 2019
- ANDA213063Taro · July 1, 2020
- ANDA202510Strides Pharma Intl · July 24, 2020
- ANDA213474Aiping Pharm Inc · July 28, 2020
- ANDA210268Chartwell Rx · September 4, 2020
- ANDA210675Epic Pharma LLC · October 16, 2020
- ANDA211618Velzen Pharma Pvt · March 1, 2021
- ANDA211619Leading · March 9, 2021
- ANDA214908Appco · April 1, 2021
- ANDA215076Alembic · April 21, 2021
- ANDA215710Mankind Pharma · February 9, 2022
- ANDA215113Msn · June 24, 2022
- ANDA215408Teva Pharms · February 17, 2023
- ANDA214823Msn · April 3, 2023
- ANDA202761Zydus Lifesciences · August 16, 2023
- ANDA212357Amneal · August 16, 2023
- ANDA217975Unique · August 21, 2023
- ANDA218564Ajanta Pharma Ltd · July 1, 2024
- ANDA216041Aurobindo Pharma Ltd · July 25, 2024
- ANDA219058Taro · August 6, 2025
- ANDA213919Sun Pharma Canada · April 28, 2026
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
July 25, 2025 · Class II · Ongoing · D-0566-2025
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Doxepin Hydrochloride Capsules, USP, 10 mg, 100 Capsules, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panela v 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, — Alembic Pharmaceuticals Limited
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Zonalon, Mylan Pharmaceuticals Inc., effective June 14, 2017; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →